Post-earnings recap
Reported
Tue, May 5, 2026
EPS actual
$-1.65
EPS est.
$-1.55
EPS surprise
-6.45%
1-day move
-0.07%
Disc Medicine reported a narrower loss per share than expected, which is a positive sign for investors. However, the lack of revenue and guidance may raise concerns about future performance. The stock reacted slightly down by 0.07%, indicating that investors are cautious following the earnings report.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.65 | $-1.73 | +6.45% |
| Revenue | $0M | $0M | — |
No transcript is on record for the earnings call, so the analysis is based solely on numerical results.
Disc Medicine, Inc. is a biotechnology company focused on developing innovative therapies for patients with rare blood disorders. Operating in the health care sector, the company aims to address significant unmet medical needs, which is crucial as the demand for specialized treatments continues to grow.
Last quarter
In Q4-2025, Disc Medicine reported a significant EPS loss of $-6.01, which was much worse than the expected loss of $-1.69. The stock reacted positively the next day, gaining 1.52%.
EPS beat streak
1Q
EPS beat rate
38%
Avg EPS surprise
-38.41%
Avg 1-day reaction
+0.67%
Analysts expect another challenging quarter for Disc Medicine, with a consensus EPS loss of $-1.73. The company has not provided specific guidance, leading to uncertainty among investors.
Bull case
If the company can narrow its losses and provide positive updates on its product pipeline, it could signal a turnaround, attracting investor interest.
Bear case
Continued larger-than-expected losses could raise concerns about the company's financial health and ability to fund its operations.
Key metrics to watch
EPS
-1.73Earnings per share is a key indicator of profitability, and investors will be looking for any signs of improvement or worsening losses.
Revenue
$0MAlthough no revenue is expected this quarter, any revenue generated would signal progress in the company's product development.
The print will turn on these.
Q1
Will the EPS loss be closer to the consensus estimate of $-1.73 or worse?
The market will closely watch the EPS figure as it reflects the company's financial health and operational efficiency.
Q2
Is there any revenue generated this quarter?
Any revenue would indicate progress in the company's product development and could positively influence investor sentiment.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%
Why consensus could be wrong
The Street may be underestimating the potential for a narrower EPS loss this quarter, as recent operational adjustments could lead to improved cost management.
Supporting evidence
The historical trend shows that the company has occasionally beaten EPS estimates despite a difficult environment.
Options pricing suggests a higher expected move than historical averages, indicating that traders may anticipate a surprise.
Key risk
If the EPS loss comes in better than $-1.55, it could challenge the current negative sentiment.
Pre-commit to what would confirm each case.
This quarter's performance is critical as it will provide insights into the company's ability to manage costs and develop its product pipeline.
Bull confirmed if
An EPS loss of $-1.55 or better would confirm the bull case, suggesting improved financial performance.
Bear confirmed if
An EPS loss of $-2.07 or worse would confirm the bear case, raising concerns about the company's sustainability.
What the market is pricing for the move.
Implied Move
±8.27%
Historical Avg
±3.1%
The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.
Options are pricing ±8.3% while IRON has averaged ±3.1% over the last 8 prints — setup is pricing rich.
ATM IV
0.7%
30d HV
33.2%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich in Health Care
Fade rate: 4 of 18 (22%)
This setup has occurred 30 times across Health Care in the last 2 years. 14 of 18 (78%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 6.8%, with a raw directional average of +3.0% (modestly positive historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
114.11%
of float
Insider
7.84%
of float
Holders
303
institutions
Top Holders· as of Jun 2026
FMR, LLC
4,894,473 sh · $299.4M
12.75%
-12.4%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Disc Medicine beats expectations with a smaller EPS loss, history suggests the stock could rise by around 0.08%, confirming a positive outlook.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors await further clarity from management.
Miss
A larger-than-expected EPS loss could lead to a decline of about 0.79%, reflecting ongoing concerns about the company's financial stability.
The lines on the call that would change the story.
Blackrock Inc.
2,467,899 sh · $151.0M
6.43%
8.5%
RA Capital Management, L.P.
2,450,221 sh · $149.9M
6.38%
Flat
JPMORGAN CHASE & CO
1,875,795 sh · $114.8M
4.89%
36.8%
Price (T.Rowe) Associates Inc
1,875,399 sh · $114.7M
4.88%
21.0%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.